Aural Analytics Selected for EverythingALS Study
Speech analytics solutions provider Aural Analytics has been chosen for EverythingALS' 12-month early-detection study for ALS. This study focuses on reliably capturing daily audio functionality at home using Aural Analytics' Speech Vitals technology.
"Aural Analytics is dedicated to assisting clinical researchers capture accurate insights for neurological diseases by making our non-invasive and neuro-biomarker audio technology available in their studies," said Judy Smythe, CEO of Aural Analytics, in a statement. "This collaboration with EverythingALS can transform how we study diseases using digital speech technology, thus advancing the medical field, specifically the ALS community."
EverythingALS will use Aural Analytics' Speech Vitals services to explore whether data collected by certain digital audio technology can show a change in early ALS. This study will explore the potential of data derived from speech analytics, sole-based sensors, and hand-held spirometers integrated with key demographics and existing clinical data. The data collected will be applied for characterizing the stage of the disease and tracking disease progression
Aural Analytics has already assisted nine studies on ALS treatment and completed more than 27,000 ALS speech sessions for patients. This new study could advance the detection process of ALS, including entirely new data streams and tasks to help identify measures of disease progression while providing patients with options to monitor their own symptoms without being in a clinic.
The U.S. Food and Drug Administration has registered Aural Analytics' speech analytics as a computerized cognitive assessment aid.
The U.S. National Institutes of Health this past July awarded a $1.4 million grant to Aural Analytics, a Scottsdale, Ariz., startup that is on the cutting edge of voice biomarker technology.